ArticleScientific reports2026
Nardosinone improves levodopa-induced dyskinesia in Parkinsonian rats through the microbiota-gut-brain axis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Levodopa-induced dyskinesia (LID) is a side effect of Parkinson's disease (PD) treated with L-3,4-dihydroxyphenylalanine (L-DOPA). Nardosinone is the major active component of the dried root and rhizome of Nardostachys jatamansi DC, which is effective for treating PD. The purpose of this study was to explore the effects of nardosinone on LID and the underlying mechanism involving the microbiota-gut-brain axis. A PD rat model was established with rotenone. Behavioral and immunohistochemical staining experiments were used to investigate the synergistic effect of nardosinone on L-DOPA in PD rats. Then, the LID model was established by using high-dose L-DOPA and benserazide, and the effect of nardosinone on LID was evaluated by abnormal involuntary movement scale (AIMS) and western blotting (WB). Hematoxylin‒eosin staining (on intestinal tissues), 16 S rRNA (on gut microbiota), and ELISA (on serum and brain tissues) were used to investigate the mechanism of action of nardosinone in the treatment of LID. Behavioral tests revealed that nardosinone increased the ability of L-DOPA to treat forelimb dysfunction and autonomic activity disorders in PD, and immunohistochemical staining experiments revealed that nardosinone exerted a protective effect on dopaminergic neurons as PD-induced neuronal damage was reversed, which complements the therapeutic effect of L-DOPA. AIMS and WB analyses indicated that high-dose L-DOPA induced LID, but nardosinone exerted an effect in reducing LID by not only improving rats' abnormal involuntary movements but also downregulating ∆FosB expression. Analysis of 16 S rRNA revealed that nardosinone can regulate the intestinal flora in rats with LID. In addition, nardosinone can protect the colonic structure and reduce intestinal permeability. Moreover, nardosinone can reduce the expression of inflammatory factors in the colon and striatum of rats with LID and improve intestinal inflammation and neuroinflammation. Nardosinone can improve the effect of L-DOPA on ameliorating motor function in PD rats while alleviating LID, and its mechanism for improving LID may be related to regulating intestinal flora balance, repairing intestinal barrier integrity, and inhibiting inflammatory responses via the microbiota-gut-brain axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.